Science blogging is somewhat of a communal exercise. At least, it should be and cool biomed blogs are a great community. One of the most invigorating aspects of blogging is finding new blogs that are worthwhile and edgy. Below I list some of my recommendations for blogs that you might not be familiar with, but […]
Cool biomed blogs you may not heard of: a drugmonkey, a med student, #CRISPR, & more Read More »
A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically,
New #CRISPR updates: Editas to go public, patent issues, dragons & more Read More »
Now we hear from the scientists on the front lines of CRISPR, covered in this post #2 of the Human Gene Editing Meeting. You can read Post #1 here. Jennifer Doudna starts off the big human gene editing science session on the current state of the human gene editing science and CRISPR. She gave an
Live Blogging #GeneEditSummit Day 1 Post #2: State of the Science, #CRISPR Read More »
The National Academy of Sciences (NAS) summit on Human Gene Editing will begin in a few days on December 1 in Washington, D.C. This summit is in part the extension of discussions that started at a more informal meeting on CRISPR earlier this year in Napa organized by Jennifer Doudna and colleagues. The NAS meeting
Live Blogging NAS Human Gene Editing Summit: #GeneEditSummit Read More »
Who will be speaking at the upcoming National Academy of Sciences (NAS) meeting on human gene editing? So far we haven’t known, but now we do (if you are eager to find out, skip to bottom of the post). The organizers of the meeting can be found here. Keep in mind that it is probable that
List of Speakers for NAS Meeting on Human Gene Editing Read More »
The US National Academy of Sciences (NAS) will hold a meeting on heritable human germline modification on December 1-3, 2015 in Washington, D.C. Invitations to the NAS meeting to individuals starting going out last week. The upcoming NAS meeting seeks to address these issues and discuss the possibility of a moratorium on clinical use of
NAS Meeting on Human Germline Modification Taking Shape Read More »
The international stem cell policy and ethics think tank, the Hinxton Group, weighed in yesterday on heritable human genetic modification with a new policy statement. The Hinxton statement is in many ways in agreement with the Baltimore, et al. Nature paper proposing a “prudent path forward” for human germline genetic modification, which came out of
Perspectives on Hinxton Human Germline Modification Statement Read More »
Professor Steven Pinker of Harvard has been making the case recently that when it comes to novel biotechnologies such as CRISPR-Cas9 that bioethics should just get out of the way. Further, he has argued that we do not need a moratorium on clinical use of CRISPR-Cas9 for human genetic modification. In fact, he says that
Why I Disagree with Steven Pinker On CRISPR Read More »
Earlier this week I posted an interview with Steven Pinker on CRISPR, human germline modification, and bioethics. With only a few exceptions, I strongly disagree with Pinker’s philosophy in these areas and I knew going into the interview that his answers would likely go against my own views. I also expected the interview would anger
Why interview Steven Pinker on my blog if I strongly disagree with him? Read More »
CRISPR-Cas9 gene editing technology is red-hot right now and I’ve been doing interviews with various thought leaders on it, which today includes Steven Pinker. This technology has great power for research in the lab and there are hypothetical transformative clinical applications of CRISPR too. The latter efforts could include experimental attempts at reversal of disease-causing
Steven Pinker interview: case against bioethocrats & CRISPR germline ban Read More »